10/3/08 update
It's been three weeks since my last update and the Bears had quite a party while I was out of the country. And it doesn't look like they were much intimidated by my return - or the U.S. Congress. At Friday's close, the Nasdaq Composite Index was down -26.58% YTD (vs. -14.74% YTD 3 weeks ago), while the Nasdaq Biotech Index was down -4.95% YTD (vs. up 3.53% YTD 3 weeks ago). The Contest portfolios were also trashed, with the median closing down -25.65% YTD (vs. down -12.94% YTD 3 weeks ago).
At week's end, a mere 4 of the 33 Contest portfolios were in the black YTD with just 5 of the portfolios beating the NBI. Not surprisingly, GENE's portfolio remained in the lead, with a 87.2% YTD gain. ROBERT's portfolio held on to second place with a 9.6% YTD gain.
Forget your market woes and enjoy the weekend folks!
Below is the Top Ten list on 10/3/08:
10/3/08
Rank Name Total
1 GENE 87,152
2 ROBERT 9,597
3 JACK 2,317
4 CASA 1,197
5 ROCKY9 -4,194
6 SJEMM -7,559
7 BULBA -9,288
8 HAMMER -13,244
9 LJM -14,773
10 ASHLEY -16,147
There were a number of portfolio adjustments over the past three weeks:
>> IVPH was bought by CYTR with each IVPH share exchanged for a .1762 share of CYTR
>> ILMN split 2-1
>> ARI.TO was bought for US$2.322. I allocated the proceeds to the other stocks in my portfolio using 10/1/08 closing prices.
(All corrections, especially adjustments for splits, greatly appreciated.) |
